Do Clinicians Recommend Aspirin to Patients for Primary Prevention of Cardiovascular Disease?
- 706 Downloads
The United States Preventive Services Task Force (USPSTF) released updated guidelines in 2009 recommending aspirin to prevent myocardial infarction among at-risk men and stroke among at-risk women.
Our aim was to examine clinician aspirin recommendation among eligible persons based on cardiovascular risk scores and USPSTF cutoffs.
We used across-sectional analysis of a current nationally representative sample.
Participants were aged 40 years and older, and in the National Health and Nutrition Examination Survey (NHANES) (2011–2012).
We determined aspirin eligibility for cardiovascular disease (CVD) prevention for each participant based on reported and assessed cardiovascular risk factors. We assessed men’s risk using a published coronary heart disease risk calculator based on Framingham equations, and used a similar calculator for stroke to assess risk for women. We applied the USPSTF risk cutoffs for sex and age that account for offsetting risk for gastrointestinal hemorrhage. We assessed clinician recommendation for aspirin based on participant report.
Among men 45–79 years and women 55–79 years, 87 % of men and 16 % of women were potentially eligible for primary CVD aspirin prevention. Clinician recommendation rates for aspirin among those eligible were low, 34 % for men and 42 % for women. Rates were highest among diabetics (63 %), those 65 to 79 years (52 %) or those in poor health (44 %). In contrast, aspirin recommendation rates were 76 % for CVD secondary prevention. After accounting for patient factors, particularly age, eligibility for aspirin prevention was not significantly associated with receiving a clinician’s recommendation for aspirin (AOR 0.99 %; CI 0.7–1.4).
Despite an “A recommendation” from the USPSTF for aspirin for primary prevention of CVD, the majority of men and women potentially eligible for aspirin did not recall a clinical recommendation from their clinician.
KEY WORDSaspirin primary CVD prevention USPSTF guidelines
We acknowledge Carol Moulthroup for her assistance with the proofing and submission process.
Conflict of Interest
The authors declare they have no conflict of interest.
External and Internal Funding Sources
- 1.Aspirin for the prevention of cardiovascular disease: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2009;150:396–404Google Scholar
- 3.Goldstein LB, Bonito AJ, Matchar DB, Duncan PW, DeFriese GH, Oddone EZ, Paul JE, Akin DR, Samsa GP. Us national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices. Stroke. 1995;26:1607–1615.PubMedCrossRefGoogle Scholar
- 15.Horne BD, May HT, Kfoury AG, Renlund DG, Muhlestein JB, Lappe DL, Rasmusson KD, Bunch TJ, Carlquist JF, Bair TL, Jensen KR, Ronnow BS, Anderson JL. The intermountain risk score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. European journal of heart failure. 2010;12:1203–1213.PubMedCrossRefGoogle Scholar
- 16.Horne BD, Muhlestein JB, Lappe DL, Brunisholz KD, May HT, Kfoury AG, Carlquist JF, Alharethi R, Budge D, Whisenant BK, Bunch TJ, Ronnow BS, Rasmusson KD, Bair TL, Jensen KR, Anderson JL. The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Translational research : the journal of laboratory and clinical medicine. 2011;158:307–314.CrossRefGoogle Scholar
- 17.U.S. Department of Health and Human Services (DHHS) CfDCaPC, National Center for Health Statistics (NCHS). . National health and nutrition examination survey: Analytic guidelines, 1999–2010. Dhhs publication no. 2013–1361. Sept 2013Google Scholar
- 18.Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res. 2008;8:60Google Scholar
- 26.Puhan MA, Singh S, Weiss CO, Varadhan R, Sharma R, Boyd CM. Evaluation of the benefits and harms of aspirin for primary prevention of cardiovascular events: A comparison of quantitative approaches. Rockville MD; 2013Google Scholar
- 27.Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.PubMedCrossRefGoogle Scholar
- 30.Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Ngianga-Bakwin K, Grove A, Gurung B, Morrow S, Stranges S, Clarke A. Aspirin in primary prevention of cardiovascular disease and cancer: A systematic review of the balance of evidence from reviews of randomized trials. PloS one. 2013;8:e81970.PubMedCentralPubMedCrossRefGoogle Scholar
- 31.Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA. 2010;303:841–848.PubMedCrossRefGoogle Scholar
- 32.US Food and Drug Administration. Citizen’s Petition Denial Response [letter]. Docket No. FDA-1977-N-0018–2404; Rockville, MD: May 2, 2014. (FDA press release http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm).
- 33.Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC, Jr., Levy D, Watson K, Wilson PW. 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013Google Scholar
- 35.Persell SD, Lloyd-Jones DM, Friesema EM, Cooper AJ, Baker DW. Electronic health record-based patient identification and individualized mailed outreach for primary cardiovascular disease prevention: A cluster randomized trial. J Gen Intern Med. 2013;28:554–560.PubMedCentralPubMedCrossRefGoogle Scholar
- 36.Sequist TD, Gandhi TK, Karson AS, Fiskio JM, Bugbee D, Sperling M, Cook EF, Orav EJ, Fairchild DG, Bates DW. A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease. Journal of the American Medical Informatics Association : JAMIA. 2005;12:431–437.PubMedCentralPubMedCrossRefGoogle Scholar
- 37.Hemens BJ, Holbrook A, Tonkin M, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB. Computerized clinical decision support systems for drug prescribing and management: A decision-maker-researcher partnership systematic review. Implementation science : IS. 2011;6:89.PubMedCentralPubMedCrossRefGoogle Scholar
- 41.Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA. 2001;285:2370–2375.PubMedCrossRefGoogle Scholar
- 42.Prineas RJ, Le A, Soliman EZ, Zhang ZM, Howard VJ, Ostchega Y, Howard G. United states national prevalence of electrocardiographic abnormalities in black and white middle-age (45- to 64-year) and older (>/=65-year) adults (from the reasons for geographic and racial differences in stroke study). The American journal of cardiology. 2012;109:1223–1228.PubMedCentralPubMedCrossRefGoogle Scholar